Latest News

DAIICHI SANKYO INC.: Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy.

ASB RESOURCES: What's New in Business Intelligence for 2019

With the rising complexity of the business intelligence environment, the identification of trends is a key factor in effective decision-making.

MERCK: Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

OCEAN COUNTY: New App Puts Ocean County Parks and Recreation Information at Your Fingertips

Ocean County park sites and recreational activities can now be right at your fingertips thanks to a new app.

CORPORATE ESSENTIALS: How Corporate Catering Can Improve Your NJ or NYC Office

There are so many practical benefits to having corporate catering tend to your NJ or NYC company’s office refreshments and food needs.

DAIICHI SANKYO, INC: Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise.

ABCO SYSTEMS: Conveyor System Maintenance

ABCO Systems offers conveyor maintenance and here is why.

MERCK: European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.

BD: BD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL.

CELGENE CORPORATION: Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A. INC: Konica Minolta Strengthens Workplace Of The Future Offering With The Launch Of The Acuant i-Dentify 150 Scanner To Confirm Visitor Identity

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced selection of the Acuant i-Dentify™ 150 Scanner, with Wintech’s ID Scan & Validate Subscription Plug-In, to complement the ALICE® Receptionist visitor management system.

BD: BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems identify drug diversion at the 2018 American Society of Health-System Pharmacists (ASHP) Midyear Meeting

CELGENE CORPORATION: Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma.

CORPORATE ESSENTIALS: Rickaroons: The New Standard For Delicious Energy Snacks

The search for a healthy and delicious, dietary friendly energy snack is over!

MERCK: Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease.

MERCK: FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy.

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A, INC: Konica Minolta’s AccurioJet KM-1 UV Inkjet Press Offers New Opportunities to Expand Small Business Client Base

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) is pleased to announce that our Accuriojet KM-1 UV Inkjet press continues to transform small and medium-sized businesses (SMBs) by expanding their opportunities to break into new markets, offer new products, and increase profits.

Metro Business Network